Taiwan · Delayed Price · Currency is TWD OBI Pharma Statistics
Total Valuation
OBI Pharma has a market cap or net worth of TWD 3.97 billion. The enterprise value is 4.41 billion.
| Market Cap | 3.97B |
| Enterprise Value | 4.41B |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OBI Pharma has 131.58 million shares outstanding. The number of shares has increased by 8.68% in one year.
| Current Share Class | 131.58M |
| Shares Outstanding | 131.58M |
| Shares Change (YoY) | +8.68% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 6.45% |
| Owned by Institutions (%) | 2.68% |
| Float | 86.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 79.98 |
| PB Ratio | 1.77 |
| P/TBV Ratio | 2.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 88.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.44, with a Debt / Equity ratio of 0.21.
| Current Ratio | 3.44 |
| Quick Ratio | 3.25 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.27 |
| Interest Coverage | -160.80 |
Financial Efficiency
Return on equity (ROE) is -67.84% and return on invested capital (ROIC) is -35.26%.
| Return on Equity (ROE) | -67.84% |
| Return on Assets (ROA) | -34.03% |
| Return on Invested Capital (ROIC) | -35.26% |
| Return on Capital Employed (ROCE) | -83.40% |
| Weighted Average Cost of Capital (WACC) | 4.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | 5.49 |
Taxes
| Income Tax | -1.33M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.53% in the last 52 weeks. The beta is 0.07, so OBI Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.07 |
| 52-Week Price Change | -53.53% |
| 50-Day Moving Average | 30.22 |
| 200-Day Moving Average | 43.95 |
| Relative Strength Index (RSI) | 54.48 |
| Average Volume (20 Days) | 748,850 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OBI Pharma had revenue of TWD 49.68 million and -1.98 billion in losses. Loss per share was -15.07.
| Revenue | 49.68M |
| Gross Profit | -89.02M |
| Operating Income | -2.11B |
| Pretax Income | -2.21B |
| Net Income | -1.98B |
| EBITDA | -1.95B |
| EBIT | -2.11B |
| Loss Per Share | -15.07 |
Balance Sheet
The company has 802.32 million in cash and 461.79 million in debt, with a net cash position of 340.53 million or 2.59 per share.
| Cash & Cash Equivalents | 802.32M |
| Total Debt | 461.79M |
| Net Cash | 340.53M |
| Net Cash Per Share | 2.59 |
| Equity (Book Value) | 2.24B |
| Book Value Per Share | 11.14 |
| Working Capital | 804.08M |
Cash Flow
In the last 12 months, operating cash flow was -1.71 billion and capital expenditures -31.81 million, giving a free cash flow of -1.74 billion.
| Operating Cash Flow | -1.71B |
| Capital Expenditures | -31.81M |
| Depreciation & Amortization | 159.51M |
| Net Borrowing | -23.88M |
| Free Cash Flow | -1.74B |
| FCF Per Share | -13.23 |
Margins
| Gross Margin | -179.19% |
| Operating Margin | -4,250.69% |
| Pretax Margin | -4,451.32% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OBI Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.68% |
| Shareholder Yield | -8.68% |
| Earnings Yield | -49.87% |
| FCF Yield | -43.81% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 27, 2026. It was a reverse split with a ratio of 0.5.
| Last Split Date | Jan 27, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.5 |
Scores
OBI Pharma has an Altman Z-Score of 1.13 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.13 |
| Piotroski F-Score | 2 |